Implementation of Substance Use Treatment in Ambulatory Care

Discusses how a prescribing physician may prepare for a DEA visit from the DEA. Such visits are required by law for physicians prescribing buprenorphine and involve topics such as prescription and dispensing records and adherence to prescribing limits on number of patients.

Assesses differences in attractiveness of different prescription opioid products and formulations to potential individuals with substance use disorders.

Describes a brief 5-item compliance checklist for use with chronic pain patients prescribed long-term opioid therapy to ask patients about aberrant drug-related behavior over the past month. Any positive response indicates problems with adherence with opioids.

Discusses psychosocial treatment buprenorphine patients should receive.

Offers clinicians information on medications for opioid addiction treatment, including side effects, drug interactions, and take-home doses. Discusses patient counseling, associated medical problems, hepatitis C evaluation, drug testing, and pregnant women.

Provides information about the interactions of clinical significance that occur between buprenorphine or methadone and other medications.

Provides a sample treatment contract for office-based opioid addiction treatment with buprenorphine.

Provides a sample treatment agreement for buprenorphine/Naloxone.

Provides a sample treatment agreement for buprenorphine/naloxone.

Highlights criteria and patient history for those requesting to transfer from methadone to office-based buprenorphine treatment.